
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1205691/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Palifermin as primary mucositis prophylaxis in patients with B-cell Non-Hodgkin lymphoma: a case series. Pediatric Hematology and Oncology, 2022, 39, 80-82.	0.8	1
2	Hematologic complications with age in Shwachman-Diamond syndrome. Blood Advances, 2022, 6, 297-306.	5.2	23
3	Lymphocyte cytosolic protein 1 (L-plastin) I232F mutation impairs granulocytic proliferation and causes neutropenia. Blood Advances, 2022, 6, 2581-2594.	5.2	5
4	Relapse Risk for B-ALL Patients By Pre-Hematopoietic Cell Transplantation (HCT) Next-Generation Sequencing (NGS-MRD): An Interim Analysis of Observational Arm Subjects on Pediatric Transplantation and Cellular Therapy Consortium (PTCTC) ONC1701. Transplantation and Cellular Therapy, 2022, 28, S130-S131.	1.2	0
5	A randomized controlled trial of everolimus for neurocognitive symptoms in PTEN hamartoma tumor syndrome. Human Molecular Genetics, 2022, 31, 3393-3404.	2.9	10
6	Characteristics of Graft-Versus-Host Disease (GvHD) After Post-Transplantation Cyclophosphamide Versus Conventional GvHD Prophylaxis. Transplantation and Cellular Therapy, 2022, 28, 681-693.	1.2	13
7	Brachial plexus chloroma as a presenting feature of relapse in a child with KMT2A-rearranged acute lymphoblastic leukemia, a case report. Pediatric Hematology and Oncology, 2021, 38, 179-183.	0.8	1
8	Improved Clinical Outcomes with Omidubicel Versus Standard Myeloablative Umbilical Cord Blood Transplantation: Results of a Phase III Randomized, Multicenter Study. Transplantation and Cellular Therapy, 2021, 27, S33-S34.	1.2	1
9	A randomized double-blind controlled trial of everolimus in individuals with PTEN mutations: Study design and statistical considerations. Contemporary Clinical Trials Communications, 2021, 21, 100733.	1.1	11
10	Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. Blood, 2021, 138, 1429-1440.	1.4	54
11	Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation. Bone Marrow Transplantation, 2021, 56, 2826-2833.	2.4	5
12	Influence of Killer Immunoglobulin-Like Receptors and Somatic Mutations on Transplant Outcomes in Acute Myeloid Leukemia. Transplantation and Cellular Therapy, 2021, 27, 917.e1-917.e9.	1.2	3
13	Outcomes in Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia. Transplantation and Cellular Therapy, 2021, 28, 101.e1-101.e1.	1.2	7
14	A Step Toward Comprehensive Transplant Solutions for Aplastic Anemia. Transplantation, 2021, 105, 955-957.	1.0	0
15	Randomized Trial of Tacrolimus and Methotrexate Versus Tacrolimus, Reduced Dose Methotrexate, and Mycophenolate Mofetil for Prevention of Graft-Versus-Host Disease after Myeloablative Related and Unrelated Donor Allogeneic Hematopoietic Cell Transplantation. Blood, 2021, 138, 99-99.	1.4	0
16	Successful Treatment with ALVR105 for Disseminated Adenovirus Infection in an Infant after Allogeneic Hematopoietic Cell Transplantation: A Case Report. Blood, 2021, 138, 4865-4865.	1.4	1
17	Impact of Allogeneic Hematopoietic Cell Transplantation (HCT) As Consolidation Following CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy for Treatment of Relapsed Acute Lymphoblastic Leukemia (ALL). Blood, 2021, 138, 3880-3880.	1.4	4
18	Comparative effectiveness of busulfan/cyclophosphamide versus busulfan/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 160-165.	0.9	8

#	Article	IF	CITATIONS
19	The treatment of adolescents and young adults with acute lymphoblastic leukemia. Leukemia and Lymphoma, 2020, 61, 18-26.	1.3	5
20	Paediatric haematologists' attitudes regarding haematopoietic cell transplantation as treatment for sickle cell disease. British Journal of Haematology, 2020, 188, 976-984.	2,5	4
21	Influence of major histocompatibility complex class I chain-related gene A polymorphisms on cytomegalovirus disease after allogeneic hematopoietic cell transplantation. Hematology/ Oncology and Stem Cell Therapy, 2020, 13, 32-39.	0.9	7
22	Use of Thrombopoietin Receptor Agonists in Prolonged Thrombocytopenia after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, e65-e73.	2.0	40
23	Distance to treatment center is associated with survival in children and young adults with acute lymphoblastic leukemia. Cancer, 2020, 126, 5319-5327.	4.1	8
24	Quality-of-Life Trajectories in Adolescent and Young Adult versus Older Adult Allogeneic Hematopoietic Cell Transplantation Recipients. Biology of Blood and Marrow Transplantation, 2020, 26, 1505-1510.	2.0	11
25	Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2020, 26, 1459-1468.	2.0	35
26	Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1105-1123.	4.9	9
27	Safety of allogeneic hematopoietic stem cell transplantation in betaâ€ŧhalassemia patients with chronic hepatitis C infections treated at a pediatric center. Pediatric Transplantation, 2019, 23, e13520.	1.0	3
28	Conditional Long-Term Survival after Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma. Biology of Blood and Marrow Transplantation, 2019, 25, 2522-2526.	2.0	4
29	Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. Journal of Clinical Oncology, 2019, 37, 367-374.	1.6	110
30	Augmenting Non-Myeloablative BMT with Ptcy Using Thiotepa or 400 Cgy TBI Improves Engraftment in Patients with Transfusion Dependent Thalassemia: Results of a Haploidentical Transplant Consortium for Hemoglobinopathies (ICHH). Biology of Blood and Marrow Transplantation, 2019, 25, S310-S311.	2.0	6
31	Impact of germline CTC 1 alterations on telomere length in acquired bone marrow failure. British Journal of Haematology, 2019, 185, 935-939.	2.5	9
32	lmmunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study. Haematologica, 2019, 104, 1974-1983.	3.5	43
33	Rapid and Robust CD4+ and CD8+ T-, NK-, B-Cell, Dendritic Cell, and Monocyte Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, S55.	2.0	2
34	Letermovir for Secondary Cytomegalovirus (CMV) Prophylaxis in a Pediatric Stem Cell Transplant Patient. Biology of Blood and Marrow Transplantation, 2019, 25, S282-S283.	2.0	5
35	Breath analysis in gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation. Blood Advances, 2019, 3, 2732-2737.	5.2	9
36	Related and unrelated donor transplantation for β-thalassemia major: results of an international survey. Blood Advances, 2019, 3, 2562-2570.	5.2	48

#	Article	IF	CITATIONS
37	Parent and Guardian Knowledge of Hematopoietic Cell Transplantation as a Treatment Option for Sickle Cell Disease. Journal of Pediatric Hematology/Oncology, 2019, 41, 187-193.	0.6	6
38	Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes. Bone Marrow Transplantation, 2019, 54, 1281-1286.	2.4	24
39	Effect of bone marrow CD34+cells and T-cell subsets on clinical outcomes after myeloablative allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation, 2019, 54, 775-781.	2.4	14
40	No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Compared to Conventional CBT: Results of a Randomized Trial. Blood, 2019, 134, 146-146.	1.4	2
41	Prognostic Factors for Mortality among Day +100 Survivors after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1029-1034.	2.0	19
42	Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. Blood, 2018, 132, 1438-1451.	1.4	78
43	Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. Biology of Blood and Marrow Transplantation, 2018, 24, 1651-1656.	2.0	18
44	Related and Unrelated Donor Transplantation for \hat{I}^2 Thalassemia Major: Results of an International Survey. Blood, 2018, 132, 308-308.	1.4	1
45	Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2017, 23, 776-781.	2.0	3
46	Balloon Kyphoplasty for Managing Intractable Pain in Pediatric Pathologic Vertebral Fractures. Journal of Pediatric Orthopaedics, 2017, 37, e286-e291.	1.2	4
47	The association of histologic grade with acute graftâ€versusâ€host disease response and outcomes. American Journal of Hematology, 2017, 92, 683-688.	4.1	9
48	<i><scp>M</scp>ycobacterium genavense</i> â€induced spindle cell pseudotumor in a pediatric hematopoietic stem cell transplant recipient: Case report and review of the literature. Transplant Infectious Disease, 2017, 19, e12656.	1.7	9
49	Liver Transplantation for Hepatocellular Carcinoma in Young Adults: A United Network for Organ Sharing Study. Journal of Adolescent and Young Adult Oncology, 2017, 6, 286-293.	1.3	1
50	Detection of Sp110 by Flow Cytometry and Application to Screening Patients for Veno-occlusive Disease with Immunodeficiency. Journal of Clinical Immunology, 2017, 37, 707-714.	3.8	11
51	Nicord Single Unit Expanded Umbilical Cord Blood Transplantation: Final Results of a Multicenter Phase I/ II Trial. Blood, 2017, 130, 847-847.	1.4	8
52	Invasive <i>Aspergillus</i> infection requiring lobectomy in a CYP2C19 rapid metabolizer with subtherapeutic voriconazole concentrations. Pharmacogenomics, 2016, 17, 663-667.	1.3	10
53	Evaluation of Ciprofloxacin in the Treatment of BK VIRUS-Associated Hemorrhagic Cystitis in Hematopoietic CELL Transplant Recipients. Biology of Blood and Marrow Transplantation, 2016, 22, S169-S170.	2.0	Ο
54	Prognostic Effect of Bone Marrow (BM) and Peripheral Blood Stem Cell (PBSC) Donor Cell Subsets on Myeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes. Blood, 2016, 128, 660-660.	1.4	3

#	Article	IF	CITATIONS
55	Prognostic Factors for Late Mortality Among Day 100 Survivors after Allogeneic Hematopoietic Cell Transplantation (HCT). Blood, 2016, 128, 4666-4666.	1.4	0
56	Germline and Somatic Genetic Characterization of Shwachman-Diamond Syndrome. Blood, 2016, 128, 2681-2681.	1.4	0
57	Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLAâ€identical sibling donor allogeneic hematopoietic cell transplantation. American Journal of Hematology, 2015, 90, 144-148.	4.1	27
58	Single Nucleotide Gene Polymorphisms (SNP) in the Gamma Block of the Major Histocompatibility Complex (MHC) Are Independent Risk Factors for Severe Acute Graft Versus Host Disease (GVHD) in Unrelated Donor Hematopoietic Cell Transplantation (HCT). Biology of Blood and Marrow Transplantation, 2015, 21, S326-S327.	2.0	5
59	Long-term survival after high-dose chemotherapy with autologous hematopoietic cell transplantation in metastatic breast cancer. Hematology/ Oncology and Stem Cell Therapy, 2015, 8, 115-124.	0.9	3
60	Prognostic Impact of Molecular Mutations in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) on Allogeneic Hematopoietic Cell Transplant (HCT) Outcomes: Adverse Impact of TET2 Mutations. Blood, 2015, 126, 740-740.	1.4	3
61	Long-Term Outcomes after Myeloablative Allogeneic Hematopoietic Cell Transplantation for Adult Acute Lymphoblastic Leukemia. Blood, 2015, 126, 5534-5534.	1.4	0
62	Comparative Effectiveness of Fludarabine and Busulfan Versus Fludarabine and 400 cGy Total Body Irradiation Reduced Intensity Conditioning Regimens for Allogeneic Hematopoietic Cell Transplantation for AML/MDS. Blood, 2015, 126, 1920-1920.	1.4	0
63	Concurrent juvenile myelomonocytic leukemia and T″ymphoblastic lymphoma with a shared missense mutation in <i>NRAS</i> . Pediatric Blood and Cancer, 2014, 61, 946-948.	1.5	6
64	Synergistic Effect of Major Histocompatibility Complex Class I–Related Chain A and Human Leukocyte Antigen–DPB1 Mismatches in Association with Acute Graft-versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1835-1840.	2.0	17
65	HLA-Mismatch Is Associated with Worse Outcomes after Myeloablative Conditioning and Unrelated Donor Hematopoietic Cell Transplantation: A Cibmtr Analysis. Biology of Blood and Marrow Transplantation, 2014, 20, S25-S26.	2.0	1
66	Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. Blood, 2014, 124, 2596-2606.	1.4	228
67	Can We Predict Hemorrhagic Cystitis Based on BK Viremia?. Biology of Blood and Marrow Transplantation, 2013, 19, 1137-1138.	2.0	0
68	Defining Incidence, Risk Factors, and Impact on Survival of Central Line-Associated Blood Stream Infections Following Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2013, 19, 720-724.	2.0	39
69	Long-Term Outcome Of Adolescents and Young Adults (AYA) After Autologous Transplantation For Lymphoma; Single Center Experience With Bu-CY-VP16 Conditioning Therapy. Blood, 2013, 122, 4644-4644.	1.4	0
70	Defining Central Line-Associated Blood Stream Infections Following Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome Blood, 2012, 120, 3042-3042.	1.4	2
71	Omission of Methotrexate Doses Due to Toxicity Does Not Influence the Incidence of Gvhd, Relapse, or Survival. Blood, 2012, 120, 4189-4189.	1.4	1
72	Racial Differences in Prognostic Factors and Outcomes in Patients Undergoing Allogeneic Hematopoietic Cell Transplant. Blood, 2012, 120, 2020-2020.	1.4	0

#	Article	IF	CITATIONS
73	Long Term Survival After High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation in Metastatic Breast Cancer Blood, 2012, 120, 3072-3072.	1.4	Ο
74	Mycophenolate Mofetil Is a Suitable Substitute for Methotrexate for Graft Versus Host Disease Prevention in Myeloablative Allogeneic Hematopoietic Cell Transplantation with Sibling Donors. Blood, 2012, 120, 1952-1952.	1.4	1
75	Risk Factors for Vancomycin Resistant Enterococcus (VRE) Infection and Its Influence On Survival After Allogeneic Hematopoietic Progenitor Cell Transplantation (aHPCT). Blood, 2012, 120, 4147-4147.	1.4	Ο
76	Long-Term Follow-up of a Randomized Trial Comparing Cyclosporine and Short Course Methotrexate with Cyclosporine and Mycophenolate Mofetil for Graft Versus Host Disease Prophylaxis in Myeloablative HLA-Identical Sibling Hematopoietic Cell Transplantation Blood, 2012, 120, 3073-3073.	1.4	0
77	Central Line-Associated Blood Stream Infections Following Hematopoietic Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Incidence, Risk Factors, and Impact On Survival. Blood, 2012, 120, 4481-4481.	1.4	Ο
78	Acute GVHD in AML and MDS Patients Receiving Matched Related Donor (MRD) Reduced-Intensity Conditioning Allogeneic Hematopoietic Progenitor Cell Transplant (RIC-AHPCT) Correlates with Major Histocompatibility Complex Class I-Related Molecule A (MICA) Gene Polymorphisms,. Blood, 2011, 118, 4072-4072.	1.4	0
79	Fractures in children with Pompe disease: a potentiallong-term complication. Pediatric Radiology, 2007, 37, 437-445.	2.0	28